MAPT and Alzheimer disease: Interestingly, recent studies showed that selective blockade of SYK proteins markedly decreased Aβ deposition and suppressed the hyperphosphorylation of Tau across different mouse models of AD (Paris et al., 2014; Yamaguchi et al., 2020), suggesting that SYK activity might be an attractive therapeutic target for AD.